180 related articles for article (PubMed ID: 18174713)
1. Experience from the German pegvisomant observational study.
Strasburger CJ; Buchfelder M; Droste M; Mann K; Stalla GK; Saller B;
Horm Res; 2007; 68 Suppl 5():70-3. PubMed ID: 18174713
[TBL] [Abstract][Full Text] [Related]
2. The German ACROSTUDY: past and present.
Buchfelder M; Schlaffer S; Droste M; Mann K; Saller B; Brübach K; Stalla GK; Strasburger CJ;
Eur J Endocrinol; 2009 Nov; 161 Suppl 1():S3-S10. PubMed ID: 19684061
[TBL] [Abstract][Full Text] [Related]
3. Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis.
Biering H; Saller B; Bauditz J; Pirlich M; Rudolph B; Johne A; Buchfelder M; Mann K; Droste M; Schreiber I; Lochs H; Strasburger CJ;
Eur J Endocrinol; 2006 Feb; 154(2):213-20. PubMed ID: 16452533
[TBL] [Abstract][Full Text] [Related]
4. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study.
Schreiber I; Buchfelder M; Droste M; Forssmann K; Mann K; Saller B; Strasburger CJ;
Eur J Endocrinol; 2007 Jan; 156(1):75-82. PubMed ID: 17218728
[TBL] [Abstract][Full Text] [Related]
5. Pituitary tumor size in acromegaly during pegvisomant treatment: experience from MR re-evaluations of the German Pegvisomant Observational Study.
Buchfelder M; Weigel D; Droste M; Mann K; Saller B; Brübach K; Stalla GK; Bidlingmaier M; Strasburger CJ;
Eur J Endocrinol; 2009 Jul; 161(1):27-35. PubMed ID: 19411302
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY.
van der Lely AJ; Biller BM; Brue T; Buchfelder M; Ghigo E; Gomez R; Hey-Hadavi J; Lundgren F; Rajicic N; Strasburger CJ; Webb SM; Koltowska-Häggström M
J Clin Endocrinol Metab; 2012 May; 97(5):1589-97. PubMed ID: 22362824
[TBL] [Abstract][Full Text] [Related]
7. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant.
Trainer PJ; Drake WM; Katznelson L; Freda PU; Herman-Bonert V; van der Lely AJ; Dimaraki EV; Stewart PM; Friend KE; Vance ML; Besser GM; Scarlett JA; Thorner MO; Parkinson C; Klibanski A; Powell JS; Barkan AL; Sheppard MC; Malsonado M; Rose DR; Clemmons DR; Johannsson G; Bengtsson BA; Stavrou S; Kleinberg DL; Cook DM; Phillips LS; Bidlingmaier M; Strasburger CJ; Hackett S; Zib K; Bennett WF; Davis RJ
N Engl J Med; 2000 Apr; 342(16):1171-7. PubMed ID: 10770982
[TBL] [Abstract][Full Text] [Related]
8. Which patients with acromegaly are treated with pegvisomant? An overview of methodology and baseline data in ACROSTUDY.
Brue T; Castinetti F; Lundgren F; Koltowska-Häggström M; Petrossians P;
Eur J Endocrinol; 2009 Nov; 161 Suppl 1():S11-7. PubMed ID: 19684051
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.
Colao A; Pivonello R; Auriemma RS; De Martino MC; Bidlingmaier M; Briganti F; Tortora F; Burman P; Kourides IA; Strasburger CJ; Lombardi G
Eur J Endocrinol; 2006 Mar; 154(3):467-77. PubMed ID: 16498061
[TBL] [Abstract][Full Text] [Related]
10. Long-term safety and treatment outcomes of pegvisomant in Japanese patients with acromegaly: results from the post-marketing surveillance.
Yamaguchi H; Shimatsu A; Okayama A; Sato T
Endocr J; 2020 Feb; 67(2):201-210. PubMed ID: 31723069
[TBL] [Abstract][Full Text] [Related]
11. Pegvisomant: an advance in clinical efficacy in acromegaly.
Stewart PM
Eur J Endocrinol; 2003 Apr; 148 Suppl 2():S27-32. PubMed ID: 12670298
[TBL] [Abstract][Full Text] [Related]
12. [Growth hormone receptor antagonist in the treatment of acromegaly].
Hubina E; Tóth A; Kovács GL; Dénes J; Kovács L; Góth M
Orv Hetil; 2011 May; 152(18):709-14. PubMed ID: 21498159
[TBL] [Abstract][Full Text] [Related]
13. Pegvisomant: a growth hormone receptor antagonist used in the treatment of acromegaly.
Tritos NA; Biller BM
Pituitary; 2017 Feb; 20(1):129-135. PubMed ID: 27631335
[TBL] [Abstract][Full Text] [Related]
14. [Growth hormone-receptor antagonist pegvisomant].
Herrmann BL; Strasburger CJ
Dtsch Med Wochenschr; 2004 Oct; 129(44):2356-8. PubMed ID: 15497105
[No Abstract] [Full Text] [Related]
15. Pegvisomant: a novel pharmacotherapy for the treatment of acromegaly.
Paisley AN; Trainer P; Drake W
Expert Opin Biol Ther; 2004 Mar; 4(3):421-5. PubMed ID: 15006735
[TBL] [Abstract][Full Text] [Related]
16. Experience with pegvisomant in the treatment of acromegaly.
Drake WM
Growth Horm IGF Res; 2001 Jun; 11 Suppl A():S111-4. PubMed ID: 11527081
[TBL] [Abstract][Full Text] [Related]
17. ACROSTUDY: the first 5 years.
Trainer PJ
Eur J Endocrinol; 2009 Nov; 161 Suppl 1():S19-24. PubMed ID: 19684052
[TBL] [Abstract][Full Text] [Related]
18. Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly.
Neggers SJ; Franck SE; de Rooij FW; Dallenga AH; Poublon RM; Feelders RA; Janssen JA; Buchfelder M; Hofland LJ; Jørgensen JO; van der Lely AJ
J Clin Endocrinol Metab; 2014 Oct; 99(10):3644-52. PubMed ID: 24937542
[TBL] [Abstract][Full Text] [Related]
19. Pegvisomant treatment in patients with acromegaly in clinical practice: The French ACROSTUDY.
Chanson P; Brue T; Delemer B; Caron P; Borson-Chazot F; Zouater H;
Ann Endocrinol (Paris); 2015 Dec; 76(6):664-70. PubMed ID: 26596374
[TBL] [Abstract][Full Text] [Related]
20. Long-term effects of pegvisomant in patients with acromegaly.
Hodish I; Barkan A
Nat Clin Pract Endocrinol Metab; 2008 Jun; 4(6):324-32. PubMed ID: 18431372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
